:How does pranlukast hydrate prevent asthma exacerbations associated with respiratory infection?

概要

論文の詳細を見る
The efficacy of pranlukast hydrate (pranlukast) in treatment of bronchial asthma was investigated in 48 children with bronchial asthma who were given pranlukast for 6 months or longer. The prevalence of upper and lower respiratory infection was simultaneously investigated before and after the treatment period.Administration of pranlukast for six months resulted in a rating of "improved" or better in 41.7% of the children and "slightly improved" or better in 79.2% of the children. The prevalence values for cold and fever were 4.60±2.09 and 1.81±1.33, respectively, 6 months before administration. These showed a significant reduction to 3.31±2.18 (p<0.001) and 1.23±1.15 (p=0.003), respectively, after administration of pranlukast for 6 months. The number of children whose attacks were aggravated by cold also decreased. Administration of pranlukast for 12 months had similar effects.In conclusion, the results suggest that pranlukast improves asthmatic symptoms and decreases the prevalence of cold and fever.
日本小児アレルギー学会の論文